Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 12 429 INR 0.85% Market Closed
Market Cap: 159.5B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NEULANDLAB stock under the Base Case scenario is 8 066.25 INR. Compared to the current market price of 12 429 INR, Neuland Laboratories Ltd is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NEULANDLAB Relative Value
Base Case
8 066.25 INR
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10.5
P/S
P/S
Price to Sales
10.5
vs History
9
vs Industry
14
Median 3Y
3.7
Median 5Y
2.4
Industry
2.4
Forward
9.8
More Details
53.5
P/E
P/E
Price to Earnings
53.5
vs History
9
vs Industry
8
Median 3Y
25.8
Median 5Y
29.5
Industry
20.5
Forward
63.8
More Details
65.3
P/OCF
P/OCF
Price to OCF
65.3
vs History
9
vs Industry
7
Median 3Y
25.2
Median 5Y
18.9
Industry
15.6
More Details
538.7
P/FCFE
P/FCFE
Price to FCFE
538.7
vs History
19
vs Industry
1
Median 3Y
124.4
Median 5Y
124.4
Industry
23.1
More Details
11.5
P/B
P/B
Price to Book Value
11.5
vs History
11
vs Industry
5
Median 3Y
4.9
Median 5Y
2.8
Industry
2
More Details
10.4
EV/S
EV/S
Enterprise Value to Sales
10.4
vs History
9
vs Industry
13
Median 3Y
3.7
Median 5Y
2.5
Industry
2.5
Forward
9.7
More Details
20.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
20.5
vs History
9
vs Industry
11
Median 3Y
7.4
Median 5Y
5.7
Industry
4.9
More Details
42.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
42.1
vs History
7
vs Industry
9
Median 3Y
14.2
Median 5Y
14.2
Industry
12.3
Forward
40.5
More Details
50.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
50.6
vs History
7
vs Industry
8
Median 3Y
18.6
Median 5Y
18.6
Industry
15.5
Forward
46.2
More Details
64.7
EV/OCF
EV/OCF
Enterprise Value to OCF
64.7
vs History
9
vs Industry
7
Median 3Y
26.5
Median 5Y
20.3
Industry
14.1
More Details
384.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
384.5
vs History
9
vs Industry
1
Median 3Y
56
Median 5Y
61.6
Industry
17.5
More Details
10.4
EV/IC
EV/IC
Enterprise Value to IC
10.4
vs History
11
vs Industry
8
Median 3Y
3.6
Median 5Y
2.1
Industry
1.8
More Details

Multiples Across Competitors

NEULANDLAB Competitors Multiples
Neuland Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
160.3B INR 10.5 53.5 42.1 50.6
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
191.1B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
Average P/E: 26.8
53.5
26%
2.1
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
Average EV/EBITDA: 397.4
42.1
22%
1.9
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
Average EV/EBIT: 1 701.2
50.6
24%
2.1
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.6
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
NEULANDLAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
NEULANDLAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NEULANDLAB stock valuation using valuation multiples.
Wall Street Estimates
NEULANDLAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NEULANDLAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.